HDL-Based Therapy: Vascular Protection at All Stages
暂无分享,去创建一个
[1] Ren Gong,et al. Beneficial effects of high-density lipoprotein (HDL) on stent biocompatibility and the potential value of HDL infusion therapy following percutaneous coronary intervention , 2022, Medicine.
[2] P. Magnusson,et al. The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia , 2022, Cureus.
[3] M. Schindewolf,et al. Inflammatory Mediators in Atherosclerotic Vascular Remodeling , 2022, Frontiers in Cardiovascular Medicine.
[4] N. Maddu,et al. Role of Lipoproteins in the Pathophysiology of Breast Cancer , 2022, Membranes.
[5] K. Cho. The Current Status of Research on High-Density Lipoproteins (HDL): A Paradigm Shift from HDL Quantity to HDL Quality and HDL Functionality , 2022, International journal of molecular sciences.
[6] G. Marsche,et al. Dietary Strategies to Improve Cardiovascular Health: Focus on Increasing High-Density Lipoprotein Functionality , 2021, Frontiers in Nutrition.
[7] K. Socha,et al. Mercury Content in Dietary Supplements From Poland Containing Ingredients of Plant Origin: A Safety Assessment , 2021, Frontiers in Pharmacology.
[8] E. Lutgens,et al. Apolipoprotein A1 deficiency in mice primes bone marrow stem cells for T cell lymphopoiesis , 2021, Journal of cell science.
[9] G. Ferretti,et al. High density lipoproteins and oxidative stress in breast cancer , 2021, Lipids in health and disease.
[10] L. Kasselman,et al. Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target , 2021, Metabolites.
[11] K. Courneya,et al. Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance: The ERASE Randomized Clinical Trial. , 2021, JAMA oncology.
[12] C. Ayers,et al. Regional adiposity, cardiorespiratory fitness, and left ventricular strain: an analysis from the Dallas Heart Study , 2021, Journal of Cardiovascular Magnetic Resonance.
[13] K. Rye,et al. High Density Lipoproteins and Diabetes , 2021, Cells.
[14] A. Krętowski,et al. Recent Highlights of Research on miRNAs as Early Potential Biomarkers for Cardiovascular Complications of Type 2 Diabetes Mellitus , 2021, International journal of molecular sciences.
[15] A. Remaley,et al. Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases , 2021, Cells.
[16] H. Jo,et al. Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis. , 2021, Advanced drug delivery reviews.
[17] V. Ramensky,et al. The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia , 2021, Genes.
[18] K. Socha,et al. Vitamins in Alzheimer’s Disease—Review of the Latest Reports , 2020, Nutrients.
[19] Ling Li,et al. The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease , 2020, Biomolecules.
[20] Yun Zhang,et al. A novel apoA‐I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE−/− mice , 2020, British journal of pharmacology.
[21] Yang Wang,et al. Effectiveness of niacin supplementation for patients with type 2 diabetes , 2020, Medicine.
[22] J. Severens,et al. European survey on acute coronary syndrome diagnosis and revascularisation treatment: Assessing differences in reported clinical practice with a focus on strategies for specific patient cases , 2020, Journal of evaluation in clinical practice.
[23] A. Murphy,et al. Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation. , 2019, Circulation.
[24] Karin Kornmueller,et al. Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research , 2019, Molecules.
[25] E. Fisher,et al. HDL and Reverse Cholesterol Transport. , 2019, Circulation research.
[26] C. Wellington,et al. HDL from an Alzheimer's disease perspective , 2019, Current opinion in lipidology.
[27] A. Kesselheim,et al. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes , 2019, JAMA network open.
[28] D. Barisani,et al. APOA-1Milano muteins, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties in vitro and in Apoe-/- atherosclerotic mice. , 2018, International journal of cardiology.
[29] M. Yamagishi,et al. Mendelian randomization: Its impact on cardiovascular disease. , 2018, Journal of cardiology.
[30] M. Averna,et al. Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis , 2018, Front. Physiol..
[31] J. Kastelein,et al. Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial , 2018, JAMA cardiology.
[32] J. Kastelein,et al. Effect of Serial Infusions of CER-001, a Pre-&bgr; High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial , 2018, JAMA cardiology.
[33] D. Dichek,et al. In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium. , 2018, Journal of visualized experiments : JoVE.
[34] Lawrence A Leiter,et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract , 2018, European heart journal.
[35] C. Indolfi,et al. The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review , 2018, Front. Endocrinol..
[36] Minghui Wang,et al. High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in lung adenocarcinoma , 2018, Medicine.
[37] F. Kraemer,et al. SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux. , 2018, Annual review of physiology.
[38] S. Wright,et al. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients , 2018, Arteriosclerosis, thrombosis, and vascular biology.
[39] D. Dichek,et al. Apolipoprotein A-I ) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits , 2017 .
[40] J. Montaner,et al. Intravenous treatment with human recombinant ApoA-I Milano reduces beta amyloid cerebral deposition in the APP23-transgenic mouse model of Alzheimer's disease , 2017, Neurobiology of Aging.
[41] A. Keech,et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial , 2017, The Lancet.
[42] Lawrence A Leiter,et al. Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial , 2017, Diabetes, obesity & metabolism.
[43] F. Chen,et al. Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease , 2018 .
[44] A. von Eckardstein,et al. HDL cholesterol: reappraisal of its clinical relevance , 2017, Clinical Research in Cardiology.
[45] G. Dangas,et al. The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications , 2016, Coronary artery disease.
[46] S. Grinspoon,et al. Inflammation, immune activation, and cardiovascular disease in HIV. , 2016, AIDS.
[47] Wai Hang Cheng,et al. Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice. , 2016, Biochimica et biophysica acta.
[48] J. Cummings,et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease , 2016, Alzheimer's Research & Therapy.
[49] H. Kempen,et al. A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease , 2015, European heart journal. Cardiovascular pharmacotherapy.
[50] N. Fitz,et al. Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice. , 2015, Brain : a journal of neurology.
[51] D. Rader,et al. HDL re-examined , 2015, Current opinion in lipidology.
[52] J. Genest,et al. High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk , 2015, BBA clinical.
[53] L. Gordon,et al. Synthetic high-density lipoprotein-like nanoparticles as cancer therapy. , 2015, Cancer treatment and research.
[54] M. Banach,et al. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function. , 2015, Handbook of experimental pharmacology.
[55] M. Hassan. HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack , 2014, Global cardiology science & practice.
[56] Christos G Mihos,et al. Cardiovascular effects of statins, beyond lipid-lowering properties. , 2014, Pharmacological research.
[57] D. Rader,et al. HDL and cardiovascular disease , 2014, The Lancet.
[58] Sarah Parish,et al. Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.
[59] A. Kontush,et al. Unraveling the complexities of the HDL lipidome1 , 2013, Journal of Lipid Research.
[60] H. Mo,et al. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics , 2013, Front. Pharmacol..
[61] K. Hirata,et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. , 2013, Journal of atherosclerosis and thrombosis.
[62] P. Gu,et al. Effect of Ezetimibe on Insulin Secretion in db/db Diabetic Mice , 2012, Experimental diabetes research.
[63] John Spertus,et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.
[64] A. Levy,et al. HDL dysfunction in diabetes: causes and possible treatments , 2012, Expert review of cardiovascular therapy.
[65] V. Fuster,et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). , 2012, Atherosclerosis.
[66] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.
[67] P. Barter,et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. , 2011, Circulation.
[68] Bart Lammers,et al. ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis. , 2011, Current drug targets.
[69] L. Ose. Pitavastatin: finding its place in therapy , 2011, Therapeutic advances in chronic disease.
[70] Manabu T. Nakamura,et al. Synthetic dimyristoylphosphatidylcholine liposomes assimilating into high-density lipoprotein promote regression of atherosclerotic lesions in cholesterol-fed rabbits , 2010, Experimental biology and medicine.
[71] M. Sinno,et al. Impact of Medical Therapy on Atheroma Volume Measured by Different Cardiovascular Imaging Modalities , 2010, Cardiology research and practice.
[72] S. Vaessen,et al. AAV gene therapy as a means to increase apolipoprotein A-I and high-density lipoprotein- cholesterol levels: Correction of murine apoA-I deficiency , 2009 .
[73] T. Groen,et al. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease , 2009, Neurobiology of Disease.
[74] N. Pavlidis,et al. Effects of hormonal treatment on lipids in patients with cancer. , 2009, Cancer treatment reviews.
[75] C. Cummins,et al. Liver X receptors as therapeutic targets for managing cholesterol: implications for inflammatory conditions , 2009, Clinical lipidology.
[76] W. Frishman,et al. HDL Metabolism and CETP Inhibition , 2008, Cardiology in review.
[77] R Peto,et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.
[78] D. Rader,et al. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent , 2007, Cardiovascular diabetology.
[79] Judith Wylie-Rosett,et al. Diet and Lifestyle Recommendations Revision 2006: A Scientific Statement From the American Heart Association Nutrition Committee , 2006, Circulation.
[80] L. Simons,et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome , 2004, Current medical research and opinion.
[81] S. Reddy,et al. Oral D-4F Causes Formation of Pre-βHigh-Density Lipoprotein and Improves High-Density Lipoprotein–Mediated Cholesterol Efflux and Reverse Cholesterol Transport From Macrophages in Apolipoprotein E–Null Mice , 2004, Circulation.
[82] Paul Schoenhagen,et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.
[83] Е. П. Корнена,et al. Cholesterol lowering drugs. , 1993, The New Zealand medical journal.
[84] J. Hewitt,et al. The role of lipids and lipoproteins in atherosclerosis. , 1950, Science.